EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Mechanisms of Therapeutic Resistance in Hepatocellular Carcinoma

Karen Hoi Lam Li iD, Frances Sun, Samuel Chan, Roland Ching Yu Leung, Bryan Cho Wing Li, Jeffrey Sum Lung Wong, Tiffany Hoi Wing Fung, Jenny Wai Yan Lo, Alvin Hoi Wai Chan, Thomas Yau iD

International Journal of Molecular Sciences · 29.10.2026 · 27 (21) · 9690

DOI: 10.3390/ijms27219690 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.10.2026. Verfasst von Karen Hoi Lam Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) remains a major global health burden, and therapeutic resistance continues to limit the benefit from systemic treatment. Despite advances in systemic therapies, including immune checkpoint inhibitor-based combinations, antiangiogenic agents, and multitargeted tyrosine kinase inhibitors for patients with advanced HCC, primary non-response and acquired resistance are common. This review summarizes the mechanisms that underlie resistance to contemporary HCC therapies, including tumour heterogeneity, molecular pathway rewiring and crosstalk, tumour microenvironment and immune escape, epigenetic alterations, epithelial-to-mesenchymal transition, and cancer stem cell expansion. We discuss how these mechanisms limit the efficacy of current doublet and triplet regimens, and why biologically rational combinations do not consistently translate into clinical benefit. Emerging strategies to overcome resistance, including biomarker-enriched trial designs and liquid biopsy are also discussed. A deeper integration of mechanistic insights with translational biomarkers will be essential to improve treatment durability and clinical outcomes for patients with HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsDrug Resistance, NeoplasmHumansTumor MicroenvironmentNeoplastic Stem CellsEpithelial-Mesenchymal TransitionBiomarkers, TumorEpigenesis, GeneticAnimals

Stichwörter der Autor:innen

HCCbiomarkercancer stem cellsepigeneticshepatocellular carcinomaimmune checkpoint inhibitorliquid biopsytherapeutic resistancetumour microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
  • Centre of Cancer Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.

ORCID-Profile: Karen Hoi Lam Li, Thomas Yau

Zitieren

APA

Li, K. H. L., Sun, F., Chan, S., Leung, R. C. Y., Li, B. C. W., Wong, J. S. L., Fung, T. H. W., Lo, J. W. Y., Chan, A. H. W., & Yau, T. (2026). Molecular Mechanisms of Therapeutic Resistance in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 27(21), 9690. https://doi.org/10.3390/ijms27219690

Vancouver

Li KHL, Sun F, Chan S, Leung RCY, Li BCW, Wong JSL, et al. Molecular Mechanisms of Therapeutic Resistance in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2026;27(21):9690. doi:10.3390/ijms27219690

BibTeX
@article{Li2026,
  author = {Li, Karen Hoi Lam and Sun, Frances and Chan, Samuel and Leung, Roland Ching Yu and Li, Bryan Cho Wing and Wong, Jeffrey Sum Lung and Fung, Tiffany Hoi Wing and Lo, Jenny Wai Yan and Chan, Alvin Hoi Wai and Yau, Thomas},
  title = {Molecular Mechanisms of Therapeutic Resistance in Hepatocellular Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {9690},
  doi = {10.3390/ijms27219690}
}
Kostenlos starten →